Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 17:81:104303.
doi: 10.1016/j.amsu.2022.104303. eCollection 2022 Sep.

Magnitude and predictors of first-line antiretroviral therapy regimen change among HIV infected adults: A retrospective cross sectional study

Niguse Meles Alema  1 , Solomon Weldegebreal Asgedom  2 , Mahlet Maru  2 , Beletu Berihun  2 , Teklu Gebrehiwet  2 , Tesfay Mehari Atey  2 , Desalegn Getnet Demsie  1   3 , Abere Tilahun Bantie  4 , Adane Yehualaw  3 , Chernet Taferre  3 , Sofia Assen Seid  4 , Timsel Girma  4 , Mengesha Dessie Allene  5 , Sintayehu Mulugeta Tamru  6
Affiliations

Magnitude and predictors of first-line antiretroviral therapy regimen change among HIV infected adults: A retrospective cross sectional study

Niguse Meles Alema et al. Ann Med Surg (Lond). .

Abstract

Background: Regimen change remains a significant challenge towards the achievement of human immunodeficiency virus (HIV) treatment success. In developing countries where limited treatment options are available, strategies are required to ensure the sustainability and durability of the starting regimens. Nevertheless, information regarding the rate and predictors of regimen change is limited in these settings.

Objective: This study was undertaken to determine the prevalence and predictors of changes in ART regimens among patients initiating highly active antiretroviral therapy (HAART) at XX.

Materials and methods: An institutional based retrospective cross-sectional study was conducted among adult naïve HIV patients who had initiated HAART at XX between 2010. Data were extracted by reviewing their medical charts using a pretested structured check-list. The Kaplan-Meier survival analyses were used to describe the probability of ARV regimen changes while Cox proportional hazard regression models were employed to identify the predictors of ARV regimen modifications. Data were analyzed using SPSS version 21 software, and statistical significant was deemed at p < 0.05.

Results: A total of 770 patients were enrolled in this study of these 165 (21.43%) had their ART regimen modified at least once. Drug toxicity was the main reason for regimen change followed by TB comorbidity, and treatment failure. Positive baseline TB symptoms (aHR = 1.63, p = 0.037), and Zidovudine based regimen (aHR = 1.76, p = 0.011) as compared to Stavudine based regimen were at higher risk of ART modification. Conversely, urban residence, baseline World Health organization (WHO) stage 2 as compared to WHO stage 1, baseline CD4 count ≥301 as compared to CD4 count ≤200 were at lower risk of ART modification.

Conclusion: The rate of initial HAART regimen change was found to be high. Thus, less toxic and better tolerated HIV treatment options should be available and used more frequently. Moreover, early detection and initiation of ART by the government is highly demanded to maximize the benefit and reduce risk of ART modifications.

Keywords: Adult HIV patients; Ethiopia; HAART change; Predictors; Prevalence; Reasons.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage distribution of frequently changed ARV regimen of HIV patients at ACSH from 2010 to 2020.
Fig. 2
Fig. 2
Percentage distribution of ARV regimen modified with respect to the follow-up months among HIV patients in at ACSH from 2010 to 2020.
Fig. 3
Fig. 3
Reasons of ART modification among HIV patients who changed their first line ART.
See this image and copyright information in PMC

References

    1. Bokore A., Korme B., Bayisa G. Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study. BMC Pharmacol. Toxicol. 2018;19(1):1–8. - PMC - PubMed
    1. Global H. Geneva UNAIDS; 2019. AIDS Statistics—2018 Fact Sheet.
    1. Wang H., Wolock T.M., Carter A., Nguyen G., Kyu H.H., Gakidou E., et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–e387. - PMC - PubMed
    1. Ataro Z., Motbaynor B., Weldegebreal F., Sisay M., Tesfa T., Mitiku H., et al. Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: a systematic review and meta-analysis. BMC Pharmacol. Toxicol. 2019 Nov 1;20(1):1–63. doi: 10.1186/s40360-019-0361-3. [Internet], [cited 2022 Jun 3];20(1):63. Available from: - DOI - PMC - PubMed
    1. Low Y.S., Islahudin F., Razali K.A.M., Adnan S. Modification of initial highly active antiretroviral therapy (HAART) regimen in paediatric HIV patients. Open AIDS J. 2018;12(12):11–19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850481/ [Internet] Mar 12 [cited 2022 Jun 3];12:11–9. Available from: - PMC - PubMed